COX2 依赖性抑制抗癌免疫。

IF 14.3 1区医学 Q1 ONCOLOGY

Trends in cancer Pub Date : 2024-07-01 Epub Date: 2024-05-30 DOI:10.1016/j.trecan.2024.05.006

María Cecilia Lira, Lorenzo Galluzzi, Claire Vanpouille-Box

引用次数: 0

摘要

众所周知，前列腺素 E2（PGE2）可促进癌细胞增殖，同时抑制抗癌免疫，从而促进肿瘤进展。Lacher 等人和 Morotti 等人的最新数据表明，PGE2 抑制肿瘤靶向免疫反应的机制之一是下调白细胞介素 2（IL2）受体，从而抑制 T 细胞的线粒体代谢。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

COX2-dependent suppression of anticancer immunity.

Prostaglandin E₂ (PGE₂) is well known to promote tumor progression by boosting cancer cell proliferation while inhibiting anticancer immunity. Recent data from Lacher et al. and Morotti et al. demonstrate that one of the mechanisms through which PGE₂ suppresses tumor-targeting immune responses involves downregulation of interleukin 2 (IL2) receptors and consequent inhibition of mitochondrial metabolism in T cells.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Trends in cancer Medicine-Oncology

CiteScore

28.50

自引率

0.50%

发文量

138

期刊介绍： Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine. Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.